NDC 14537-0817-75: ACD A Citric Acid Monohydrate, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .8 g/100mL; 2.45 g/100mL; 2.2 g/100mL Injection, Solution
This is a package of ACD A Citric Acid Monohydrate, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .8 g/100mL; 2.45 g/100mL; 2.2 g/100mL Injection, Solution from Terumo BCT, Ltd., first listed with the FDA Feb 2002 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 14537-817-75 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 14537 labeler · 817 product · 75 package
- Package marketed since
- Feb 25, 2002
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 1453781775 9
- FDA record last changed
- Nov 19, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 079367
- GCN: 45859
- HICL (First Databank): 015151
- AHFS class code: 20:12.04.92
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 14537-0817-75 You're viewing this Main listing | 12 BAG in 1 CARTON / 750 mL in 1 BAG | 2002-02-25 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Acd A .8 g/100mL; 2.45 g/100mL; 2.2 g/100mLthis 14537-0817-75 | Terumo | 750 ml | — | — | FDA listed | — |
| Acd A .8 g/100mL; 2.45 g/100mL; 2.2 g/100mL 14537-0810-12 | Terumo | 750 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Terumo BCT, Ltd. labeler code 14537
- ACD A Citric Acid Monohydrate, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .8 g/100mL; 2.45 g/100mL; 2.2 g/100mL Injection, Solution NDC 14537-810-12
- Anticoagulant Citrate Dextrose (ACD-A) Dextrose Monohydrate, sodium citrate, unspecified form, and Citric Acid Monohydrate .245 g/10mL; .22 g/10mL; .08 g/10mL Solution NDC 14537-820-03
- Additive Formula 3 Dextrose Monohydrate, TRISODIUM CITRATE DIHYDRATE, Sodium Chloride, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, Citric Acid Monohydrate, and Adenine 1.1 g/100mL; .59 g/100mL; .41 g/100mL; .28 g/100mL; .042 g/100mL; .03 g/100mL Solution NDC 14537-832-03
- Additive Formula 3 Dextrose Monohydrate, TRISODIUM CITRATE DIHYDRATE, Sodium Chloride, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, Citric Acid Monohydrate, and Adenine 1.1 g/100mL; .59 g/100mL; .41 g/100mL; .28 g/100mL; .042 g/100mL; .03 g/100mL Solution NDC 14537-833-03
- Sodium Citrate 4% w/v Anticoagulant TRISODIUM CITRATE DIHYDRATE 4 g/100mL Injection, Solution NDC 14537-881-25
- Sodium Citrate w/v Anticoagulant TRISODIUM CITRATE DIHYDRATE 4 g/100mL Injection, Solution NDC 14537-883-03
- ACD A Dextrose Monohydrate, Sodium Citrate, and Citric Acid Monohydrate 2.45 g/100mL; 2.2 g/100mL; .8 g/100mL Injection, Solution NDC 14537-967-75
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is an anticoagulant for blood collection for use only with apheresis devices. [See Dosage and Administration (2) .] ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is an anticoagulant for blood collection for use only with apheresis devices. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is added to tubing sets during apheresis procedures. ( 2 ) ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A may only be used with apheresis devices. For instructions on the use of the solution see the apheresis device operator's manual.
( 2.1 ) Follow the directions for connecting the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A bag to the apheresis system. ( 2.2 )
2.1General Dosing Information ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is added to tubing sets during apheresis procedures. The solution is connected to the tubing set in an apheresis collection. The recommended dose is determined by the apheresis device and metered into the tubing set by the apheresis device.
It is not intended for direct intravenous infusion. For instructions on the use of the solution with the apheresis device and tubing set, see the device operator's manual.
2.2Administration Ensure solution is the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A and is within the expiration date. Inspect the bag. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration.
Use only if solution is clear and free of particulate matter. Protect from sharp objects. Directions for Connecting the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A bag to the apheresis device.
At the prompt to connect anticoagulant to the apheresis device tubing set: Remove the overwrap by pulling down at notch, and remove the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A bag. Before use, perform the following checks [See Warnings and Precautions (5) .] : Check for leaks by gently squeezing the bag. If leaks are found, discard the bag.
Ensure that the solution is the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A and is within the expiration date. Inspect the solution in adequate light. Bags showing cloudiness, haze, or particulate matter should not be used.
Remove the protective cap from the port on the bag. Connect the bag to the apheresis device tubing set using aseptic technique and hang the solution. Break the frangible connector.
When you break frangible connectors, bend them in both directions to ensure that you break them completely. Failure to do so may result in restricted flow. Proceed according to the apheresis device operator's manual.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS 500 mL or 750 mL ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is a sterile solution in a polyolefin bag. Each 100 mL contains: (%w/v) Citric Acid, Monohydrate 0.8 g; Dextrose Monohydrate 2.45 g; Sodium Citrate Dihydrate 2.2 g; and Water for Injection. 500 mL or 750 mL sterile fluid in polyolefin bag. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS DO NOT INFUSE ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A DIRECTLY TO THE PATIENTS. DO NOT INFUSE ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A DIRECTLY TO THE PATIENTS. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Verify that the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A has been securely attached to the Anticoagulant (AC) line on the system tubing set. Use aseptic technique throughout all procedures to ensure donor safety and quality. Do not reuse.
Discard unused or partially used solution bags. Verify that the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A has been securely attached to the Anticoagulant (AC) line on the system tubing set. Use aseptic technique throughout all procedures to ensure donor safety and quality.
( 5 )
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS Citrate reactions or toxicity may occur with the infusion and return of blood containing citrate anticoagulant. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by hypotension and possible cardiac arrhythmia.
Citrate toxicity may occur more frequently in patients who are hypothermic, have impaired liver or renal function, or have low calcium levels because of an underlying disease. Citrate reactions or toxicity may occur with the infusion and return of blood containing citrate anticoagulant. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity.
( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Terumo BCT, Inc. at 1-877-339-4228 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A has not been adequately studied in controlled clinical trials with specific populations. ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A has not been studied in controlled clinical trials with specific populations.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A acts as an extracorporeal anticoagulant by binding the free calcium in the blood. Calcium is a necessary co-factor to several steps in the clotting cascade. The following ingredients are key components of the solution: Citric acid for pH regulation Sodium Citrate anticoagulates Dextrose for isotonicity This solution has no pharmacological effect.
🧬 Mechanism of Action ▾
12.1Mechanism of Action ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A acts as an extracorporeal anticoagulant by binding the free calcium in the blood. Calcium is a necessary co-factor to several steps in the clotting cascade. The following ingredients are key components of the solution: Citric acid for pH regulation Sodium Citrate anticoagulates Dextrose for isotonicity This solution has no pharmacological effect.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is a clear solution supplied in sterile and non-pyrogenic polyolefin bags. The 750 mL bags are packaged 12 bags per case. The 500 mL bags are packaged 18 bags per case. SIZE CATALOG NUMBER NDC NUMBER 500 mL 40815 14537-815-50 750 mL 40817 14537-817-75 STORAGE Store up to 25 °C [See USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.
📦 Storage and Handling ▾
STORAGE Store up to 25 °C [See USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.
📋 Description ▾
11 DESCRIPTION ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is designed to be metered by an apheresis device in apheresis procedures, to prevent platelet activation and coagulation as blood moves throughout the extracorporeal unit (tubing set) in an apheresis procedure. The solution is sterile and non-pyrogenic, and it contains no bacteriostatic or antimicrobial agents. The formulas of the active ingredients are provided in Table 1.
Table 1: Active Ingredients Ingredients Molecular Formula Molecular Weight (%w/v) Citric Acid, Monohydrate C 6 H 8 O 7 192.12 Dextrose Monohydrate C 6 H 12 O 6 ∙ H 2 O 198.17 Sodium Citrate Dihydrate C 6 H 9 Na 3 O 9 294.10 Water for Injection H 2 O
18.00Each 100 mL of ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A contains: (%w/v) Citric Acid, Monohydrate 0.8 g; Dextrose Monohydrate 2.45 g; Sodium Citrate Dihydrate 2.2 g; and Water for Injection. The polyolefin bag is not made with natural rubber latex or PVC. The bag is made from a multilayered film.
It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions. The solution contact layer is an elasticized polyolefin. The bag is nontoxic and biologically inert.
The bag-solution unit is a closed system and is not dependent upon entry of external air during administration. The bag is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 750 mL Bag Label Anticoagulant Citrate Dextrose Solution USP (ACD) Solution A Catalog # 40817 Polyolefin Bag 750 mL NDC 14537-817-75 Sterile. Non-pyrogenic. Sterilized with Steam.
Do not use unless the solution is clear and the container is intact. Rx Only. Single use container.
Read the package insert before application. For use only with apheresis devices. See apheresis device operator's manual for complete instructions.
Caution: Not for direct intravenous infusion. Recommended storage: Store up to 25 °C. (See USP Controlled Room Temperature).
Avoid excessive heat. Protect from freezing. Each 100 mL contains: Dextrose Monohydrate USP 2.45 g Sodium Citrate Dihydrate USP 2.20 g Citric Acid Monohydrate USP 0.80 g In Water for Injection USP Manufactured by Terumo BCT, Inc.
10811 W. Collins Ave., Lakewood CO 80215, USA 777967-057 TERUMO BCT Lot Expiry Date PRINCIPAL DISPLAY PANEL - 750 mL Bag Label
PRINCIPAL DISPLAY PANEL - 500 mL Bag Label Anticoagulant Citrate Dextrose Solution USP (ACD) Solution A Catalog # 40815 Polyolefin Bag 500 mL NDC 14537-815-50 Sterile. Non-pyrogenic. Sterilized with Steam.
Do not use unless the solution is clear and the container is intact. Rx Only. Single use container.
Read the package insert before application. For use only with apheresis devices. See apheresis device operator's manual for complete instructions.
Caution: Not for direct intravenous infusion. Recommended storage: Store up to 25 °C. (See USP Controlled Room Temperature).
Avoid excessive heat. Protect from freezing. Each 100 mL contains: Dextrose Monohydrate USP 2.45 g Sodium Citrate Dihydrate USP 2.20 g Citric Acid Monohydrate USP 0.80 g In Water for Injection USP Manufactured by Terumo BCT, Inc.
10811 W. Collins Ave., Lakewood CO 80215, USA 777967-540 TERUMO BCT Lot Expiry Date PRINCIPAL DISPLAY PANEL - 500 mL Bag Label
Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |